Search
Search Results
-
Widespread presentation of brown tumors mimicking multiple myeloma
Brown tumors or osteitis fibrosa cystica has become a rare presentation of primary hyperparathyroidism in up-to-date clinical practice. Here, we...
-
Selinexor–Bortezomib–Dexamethasone: A Review in Previously Treated Multiple Myeloma
Selinexor [Nexpovio ® (EU); Xpovio ® (USA)] is a first-in-class, selective exportin-1 inhibitor. Oral selinexor once weekly in combination with...
-
Targeted single-cell proteomic analysis identifies new liquid biopsy biomarkers associated with multiple myeloma
Multiple myeloma (MM) is accompanied by alterations to the normal plasma cell (PC) proteome, leading to changes to the tumor microenvironment and...
-
Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors
Extramedullary multiple myeloma (EMM) is an aggressive form of multiple myeloma (MM). This study represents the most comprehensive next-generation...
-
Enhancing multiple myeloma staging: a novel cell death risk model approach
The prognostication of survival trajectories in multiple myeloma (MM) patients presents a substantial clinical challenge. Leveraging transcriptomic...
-
Therapeutic progress in relapsed/refractory multiple myeloma
Improvement in the therapeutics for multiple myeloma (MM) has been continuously developed owing to the application of novel drugs and technologies in...
-
Maintenance therapy after allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma
In the last two decades, proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and monoclonal antibodies have greatly improved the overall...
-
Identification and evaluation of a six-lncRNA prognostic signature for multiple myeloma
PurposeMultiple myeloma (MM) is the second most common hematologic malignancy, and there is no cure for this disease. This study aimed to explore the...
-
Multiple Myeloma: Current Clinical Landscape and Compounding Costs
Purpose of ReviewThe treatment landscape of multiple myeloma (MM) has evolved resulting in MM becoming a chronic condition. The costs of MM therapies...
-
Perioperative management of a morbidly obese patient with multiple myeloma for spine surgery—when the problem doubles up!
BackgroundMultiple myeloma (MM) patients are prone to pathological fractures due to osteolytic bone lesions. With improved perioperative care,...
-
The casual relationship between autoimmune diseases and multiple myeloma: a Mendelian randomization study
Observational studies showed possible associations between systemic lupus erythematosus and multiple myeloma. However, whether there is a casual...
-
Response-Adapted Therapy for Newly Diagnosed Multiple Myeloma
Purpose of ReviewThe development of potent novel agents has improved outcomes for patients with multiple myeloma (MM). Heterogeneity of response to...
-
Diagnostic value of LGE and T1 map** in multiple myeloma patients’heart
BackgroundUnidentified heart failure occurs in patients with multiple myeloma when their heart was involved. CMR with late gadolinium enhancement...
-
TGF-β: an active participant in the immune and metabolic microenvironment of multiple myeloma
Although substantial quantities of potent therapies for multiple myeloma (MM) have been established, MM remains an incurable disease. In recent...
-
RUNX2 promotes the suppression of osteoblast function and enhancement of osteoclast activity by multiple myeloma cells
RUNX2 is a transcription factor that participates in osteoblast differentiation and chondrocyte maturation and plays an important role in the...
-
Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study
Elotuzumab-based regimens are sometimes selected for multiple myeloma treatment after daratumumab-based regimens. However, there has been...
-
Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
Patients with multiple myeloma-bearing translocation t(11;14) have recently been shown to benefit from the apoptosis-inducing drug venetoclax;...
-
The establishment of a multiple myeloma clinical registry in the Asia–Pacific region: The Asia–Pacific Myeloma and Related Diseases Registry (APAC MRDR)
BackgroundMultiple myeloma (MM) is the second most common haematological cancer worldwide. Along with related diseases including monoclonal...
-
Mitochondrial dysfunction and drug targets in multiple myeloma
Multiple myeloma (MM) is the second most common hematological cancer that has no cure. Although currently there are several novel drugs, most MM...
-
Is surgical indication in multiple myeloma a poor prognosis sign? SEER database analysis
AimThis study aims to investigate demographic data, survival rates, and the relationship of these rates with surgery in a large case series including...
